Mycophenolate mofetil

Mycophenolate mofetil Reactions 1704, p271 - 2 Jun 2018 Oral mucositis and diarrhoea: 2 case reports In a prospective study of 10 patients, two patients [ages and sexes not stated] were described, out of whom one patient developed oral mucositis and the other patient developed diarrhoea during treatment with mycophenolate mofetil for graft versus host disease (GVHD) prophylaxis. The patients underwent allogeneic haematopoietic stem cell transplantation for haematologic malignancies following unspecified conditioning therapy. On day 0 of the transplantation, the patients started receiving treatment with IV mycophenolate mofetil 1000mg over 2 hours [frequency not clearly stated] and another drug for GVHD prophylaxis. On day 1 of the transplantation, the patients started receiving filgrastim. The patients received the IV mycophenolate mofetil therapy for 10 days. On day 11 of the GVHD prophylaxis treatment, the IV mycophenolate mofetil was switched to oral mycophenolate mofetil at the same dose of 1000mg. However, one patient developed grade III oral mucositis, while the other patient developed grade III diarrhoea during the mycophenolate mofetil treatment. Both the conditions were transient and resolved without discontinuation of mycophenolate mofetil therapy [times to reactions onsets not stated]. The patients were treated with mycophenolate mofetil for 30 days. Author comment: "Individual cases of transient and curable grade III oral mucositis and diarrhea were observed; however, [mycophenolate mofetil] was not discontinued." Kurata K, et al. Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. Cancer Chemotherapy and Pharmacology 81: 839-846, No. 5, May 2018. Available from: URL: http://doi.org/10.1007/s00280-018-3550-7 - Japan 803322950 » Editorial comment: Details of this case report have previously been published [see Reactions 1702 p188; 803320494]. 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Mycophenolate mofetil

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/mycophenolate-mofetil-zf2np5672P
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46914-5
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p271 - 2 Jun 2018 Oral mucositis and diarrhoea: 2 case reports In a prospective study of 10 patients, two patients [ages and sexes not stated] were described, out of whom one patient developed oral mucositis and the other patient developed diarrhoea during treatment with mycophenolate mofetil for graft versus host disease (GVHD) prophylaxis. The patients underwent allogeneic haematopoietic stem cell transplantation for haematologic malignancies following unspecified conditioning therapy. On day 0 of the transplantation, the patients started receiving treatment with IV mycophenolate mofetil 1000mg over 2 hours [frequency not clearly stated] and another drug for GVHD prophylaxis. On day 1 of the transplantation, the patients started receiving filgrastim. The patients received the IV mycophenolate mofetil therapy for 10 days. On day 11 of the GVHD prophylaxis treatment, the IV mycophenolate mofetil was switched to oral mycophenolate mofetil at the same dose of 1000mg. However, one patient developed grade III oral mucositis, while the other patient developed grade III diarrhoea during the mycophenolate mofetil treatment. Both the conditions were transient and resolved without discontinuation of mycophenolate mofetil therapy [times to reactions onsets not stated]. The patients were treated with mycophenolate mofetil for 30 days. Author comment: "Individual cases of transient and curable grade III oral mucositis and diarrhea were observed; however, [mycophenolate mofetil] was not discontinued." Kurata K, et al. Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. Cancer Chemotherapy and Pharmacology 81: 839-846, No. 5, May 2018. Available from: URL: http://doi.org/10.1007/s00280-018-3550-7 - Japan 803322950 » Editorial comment: Details of this case report have previously been published [see Reactions 1702 p188; 803320494]. 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off